JP7522100B2 - 標的特異的な外来遺伝子の導入方法 - Google Patents

標的特異的な外来遺伝子の導入方法 Download PDF

Info

Publication number
JP7522100B2
JP7522100B2 JP2021512163A JP2021512163A JP7522100B2 JP 7522100 B2 JP7522100 B2 JP 7522100B2 JP 2021512163 A JP2021512163 A JP 2021512163A JP 2021512163 A JP2021512163 A JP 2021512163A JP 7522100 B2 JP7522100 B2 JP 7522100B2
Authority
JP
Japan
Prior art keywords
dna
cell
cells
introducing
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021512163A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020204055A5 (https=
JPWO2020204055A1 (https=
Inventor
将大 小松
健太 小村
裕二 若原
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of JPWO2020204055A1 publication Critical patent/JPWO2020204055A1/ja
Publication of JPWO2020204055A5 publication Critical patent/JPWO2020204055A5/ja
Application granted granted Critical
Publication of JP7522100B2 publication Critical patent/JP7522100B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2021512163A 2019-04-02 2020-04-01 標的特異的な外来遺伝子の導入方法 Active JP7522100B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019070329 2019-04-02
JP2019070329 2019-04-02
PCT/JP2020/014980 WO2020204055A1 (ja) 2019-04-02 2020-04-01 標的特異的な外来遺伝子の導入方法

Publications (3)

Publication Number Publication Date
JPWO2020204055A1 JPWO2020204055A1 (https=) 2020-10-08
JPWO2020204055A5 JPWO2020204055A5 (https=) 2024-01-23
JP7522100B2 true JP7522100B2 (ja) 2024-07-24

Family

ID=72668649

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021512163A Active JP7522100B2 (ja) 2019-04-02 2020-04-01 標的特異的な外来遺伝子の導入方法

Country Status (12)

Country Link
US (1) US12344859B2 (https=)
EP (1) EP3950938A4 (https=)
JP (1) JP7522100B2 (https=)
KR (1) KR102655024B1 (https=)
CN (1) CN113661238B (https=)
AU (1) AU2020252840B2 (https=)
CA (1) CA3134705A1 (https=)
IL (1) IL286630B2 (https=)
MX (1) MX2021011903A (https=)
SG (1) SG11202110076PA (https=)
TW (1) TWI851703B (https=)
WO (1) WO2020204055A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025216715A1 (en) * 2024-04-12 2025-10-16 Agency For Science, Technology And Research Identification of transcriptional hotspots in cho cells

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002526071A (ja) 1998-09-22 2002-08-20 ブリストル−マイヤーズ スクイブ カンパニー トランスフェクションした細胞中の組換えタンパク質発現増大のためのホットスポットを含む発現ベクター
WO2008151219A1 (en) 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
JP2015519914A (ja) 2012-06-22 2015-07-16 ロンザ バイオロジクス ピーエルシー 部位特異的組込み
JP2017535258A (ja) 2014-10-23 2017-11-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 新規ｃｈｏ組込み部位およびその使用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2707189B1 (fr) 1993-07-09 1995-10-13 Gradient Ass Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
US6800457B2 (en) 1998-09-22 2004-10-05 Bristol-Myers Squibb Company Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
CN1182244C (zh) * 1999-05-10 2004-12-29 中外制药株式会社 培养细胞的方法
DE60140474D1 (de) 2000-09-08 2009-12-24 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
CA2418835A1 (en) 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
CN1618955A (zh) * 2003-11-20 2005-05-25 中国人民解放军军事医学科学院生物工程研究所 一种CHO/dhfr－细胞定点整合表达系统
JP4818936B2 (ja) * 2005-01-05 2011-11-16 中外製薬株式会社 細胞の培養方法およびその利用
JP2007325571A (ja) 2006-06-09 2007-12-20 Toto Ltd 組換え哺乳類動物細胞を用いたタンパク質生産方法
CA2659574C (en) 2006-08-02 2017-04-25 The Uab Research Foundation Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity
EP3176263A1 (en) 2007-08-10 2017-06-07 Toto Ltd. Method of producing recombinant mammalian cells
US8252557B2 (en) * 2008-10-28 2012-08-28 Chugai Seiyaku Kabushiki Kaisha Peptide-containing culture medium for culturing animal cell
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
US20130034875A1 (en) * 2009-10-01 2013-02-07 Toto Ltd. Dna construct, and process for production of recombinant cho cell using same
AU2012240164A1 (en) 2011-04-05 2013-11-14 The Scripps Research Institute Chromosomal landing pads and related uses
BR112015031639A2 (pt) 2013-06-19 2019-09-03 Sigma Aldrich Co Llc integração alvo
WO2015092735A1 (en) * 2013-12-20 2015-06-25 Novartis Ag Novel eukaryotic cells and methods for recombinantly expressing a product of interest
JP6858559B2 (ja) 2014-08-20 2021-04-14 中外製薬株式会社 蛋白質溶液の粘度測定方法
CN104818253B (zh) * 2015-03-24 2018-03-09 成都贝爱特生物科技有限公司 靶向定点整合cho细胞系的改造及其用途
DE102015222931A1 (de) * 2015-11-20 2017-05-24 Continental Teves Ag & Co. Ohg Anordnung zur Messung eines durch Bremskraft erzeugten Verschiebeweges
EA201892137A1 (ru) 2016-04-20 2019-03-29 Регенерон Фармасьютикалз, Инк. Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию
US11512144B2 (en) 2016-04-20 2022-11-29 Regeneran Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of an expression-enhancing loci
EP4130280A3 (en) 2016-12-20 2023-04-19 Development Center for Biotechnology Targeted integration sites in chinese hamster ovary cell genome
SG11202000966XA (en) * 2017-08-11 2020-02-27 Boehringer Ingelheim Int Integration sites in CHO cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002526071A (ja) 1998-09-22 2002-08-20 ブリストル−マイヤーズ スクイブ カンパニー トランスフェクションした細胞中の組換えタンパク質発現増大のためのホットスポットを含む発現ベクター
WO2008151219A1 (en) 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
JP2015519914A (ja) 2012-06-22 2015-07-16 ロンザ バイオロジクス ピーエルシー 部位特異的組込み
JP2017535258A (ja) 2014-10-23 2017-11-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 新規ｃｈｏ組込み部位およびその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Database GenBank [online], NCBI Reference Sequence: NW_003614838.1，Definition: Cricetulus griseus unplaced genomic scaffold, CriGri_1.0 scaffold6779, whole genome shotgun sequence，インターネット <URL: https:// www.ncbi.nlm.nih.gov/nuccore/NW_003614838.1>，[retrieved on 11 June 2020]

Also Published As

Publication number Publication date
CN113661238A (zh) 2021-11-16
EP3950938A4 (en) 2023-01-18
IL286630B2 (en) 2025-05-01
US20220170047A1 (en) 2022-06-02
BR112021018313A2 (pt) 2021-11-23
MX2021011903A (es) 2021-10-26
CA3134705A1 (en) 2020-10-08
AU2020252840A1 (en) 2021-11-04
KR20210146362A (ko) 2021-12-03
CN113661238B (zh) 2024-08-27
IL286630A (en) 2021-12-01
TWI851703B (zh) 2024-08-11
US12344859B2 (en) 2025-07-01
SG11202110076PA (en) 2021-10-28
IL286630B1 (en) 2025-01-01
KR102655024B1 (ko) 2024-04-04
EP3950938A1 (en) 2022-02-09
JPWO2020204055A1 (https=) 2020-10-08
AU2020252840B2 (en) 2025-01-23
WO2020204055A1 (ja) 2020-10-08
TW202043478A (zh) 2020-12-01

Similar Documents

Publication Publication Date Title
JP5117542B2 (ja) 組換え第ｖｉｉｉ因子を高発現させるためのｂｈｋ細胞
US10563223B2 (en) Intergenic elements for enhancing gene expression
US10563222B2 (en) Promoters for high level expression
JP2012070744A (ja) 哺乳類βアクチンプロモーターを利用した発現系
US9365637B2 (en) Antiviral agent, abzyme, primer set, method for producing polynucleotide, and method for producing polypeptide
JP2022044609A (ja) 産生細胞株エンハンサー
CN113195712A (zh) 突变型piggyBac转座酶
EP3138917A1 (en) Method for the expression of polypeptides using modified nucleic acids
CN102498212B (zh) Cho/cert细胞系
JP7522100B2 (ja) 標的特異的な外来遺伝子の導入方法
JP2015501642A (ja) 発現カセット
EP3159411B1 (en) Vector comprising gene fragment for enhancement of recombinant protein expression and use thereof
HK40057590A (en) Method of introducing target-specific foreign gene
HK40057590B (zh) 引入靶特异性外源基因的方法
CN120380147A (zh) 截短的绝缘子及其应用
BR112021018313B1 (pt) Métodos para introdução de um dna exógeno codificando um polipeptídeo de interesse dentro de uma célula cho, e para produção de um polipeptídeo
JP2022543852A (ja) 改変されたヒト可変ドメイン
US20240076405A1 (en) Expression vectors for immunoglobulins and applications thereof
JP4958905B2 (ja) ペプチド鎖発現を増大させるための物質および方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240115

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240321

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240614

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240627

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240711

R150 Certificate of patent or registration of utility model

Ref document number: 7522100

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150